[{"address1": "5850 San Felipe St.", "address2": "Suite 500", "city": "Houston", "state": "TX", "zip": "77057", "country": "United States", "phone": "800 587 8170", "website": "https://coyatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Howard H. Berman Ph.D.", "age": 50, "title": "Executive Chair", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 830000, "exercisedValue": 0, "unexercisedValue": 189566}, {"maxAge": 1, "name": "Dr. Arun  Swaminathan Ph.D.", "age": 55, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 627084, "exercisedValue": 0, "unexercisedValue": 107332}, {"maxAge": 1, "name": "Dr. Fred  Grossman D.O., FAPA", "age": 62, "title": "President & Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 670600, "exercisedValue": 0, "unexercisedValue": 51766}, {"maxAge": 1, "name": "Mr. David S. Snyder", "age": 64, "title": "CFO & COO", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 595000, "exercisedValue": 0, "unexercisedValue": 313183}, {"maxAge": 1, "name": "Dr. Michelle  Frazier Ph.D.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Aaron  Thome Ph.D.", "title": "Head of Neuroinflammation Platform", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  King M.S.", "title": "Senior VP of Program Management & Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.75, "open": 5.79, "dayLow": 5.64, "dayHigh": 6.23, "regularMarketPreviousClose": 5.75, "regularMarketOpen": 5.79, "regularMarketDayLow": 5.64, "regularMarketDayHigh": 6.23, "payoutRatio": 0.0, "beta": 0.215, "forwardPE": -4.67672, "volume": 70903, "regularMarketVolume": 70903, "averageVolume": 59322, "averageVolume10days": 58300, "averageDailyVolume10Day": 58300, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 97772680, "fiftyTwoWeekLow": 4.65, "fiftyTwoWeekHigh": 10.24, "priceToSalesTrailing12Months": 26.531843, "fiftyDayAverage": 5.85564, "twoHundredDayAverage": 6.307075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 60638116, "profitMargins": 0.0, "floatShares": 12571345, "sharesOutstanding": 16725000, "sharesShort": 261095, "sharesShortPriorMonth": 318364, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0156, "heldPercentInsiders": 0.07016, "heldPercentInstitutions": 0.28065002, "shortRatio": 6.03, "shortPercentOfFloat": 0.0168, "impliedSharesOutstanding": 16725000, "bookValue": 1.995, "priceToBook": 2.9302757, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -17135632, "trailingEps": -1.07, "forwardEps": -1.25, "enterpriseToRevenue": 16.455, "enterpriseToEbitda": -3.123, "52WeekChange": -0.049586773, "SandP52WeekChange": 0.12632763, "quoteType": "EQUITY", "currentPrice": 5.8459, "targetHighPrice": 20.0, "targetLowPrice": 14.0, "targetMeanPrice": 16.75, "targetMedianPrice": 16.75, "recommendationKey": "none", "numberOfAnalystOpinions": 6, "totalCash": 35530624, "totalCashPerShare": 2.124, "ebitda": -19416270, "totalDebt": 0, "quickRatio": 8.185, "currentRatio": 8.84, "totalRevenue": 3685107, "revenuePerShare": 0.233, "returnOnAssets": -0.32064998, "returnOnEquity": -0.52114, "grossProfits": -10256464, "freeCashflow": -10292757, "operatingCashflow": -15262971, "revenueGrowth": 1.033, "grossMargins": -2.7832198, "ebitdaMargins": 0.0, "operatingMargins": -29.768898, "financialCurrency": "USD", "symbol": "COYA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 1.6678271, "regularMarketPrice": 5.8459, "corporateActions": [], "regularMarketTime": 1751393830, "exchange": "NCM", "messageBoardId": "finmb_700238507", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Coya Therapeutics, Inc.", "marketState": "REGULAR", "regularMarketChange": 0.09590006, "regularMarketDayRange": "5.64 - 6.23", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 59322, "fiftyTwoWeekLowChange": 1.1959, "fiftyTwoWeekLowChangePercent": 0.25718278, "fiftyTwoWeekRange": "4.65 - 10.24", "fiftyTwoWeekHighChange": -4.3940997, "fiftyTwoWeekHighChangePercent": -0.4291113, "fiftyTwoWeekChangePercent": -4.9586773, "epsTrailingTwelveMonths": -1.07, "epsForward": -1.25, "epsCurrentYear": -1.70667, "priceEpsCurrentYear": -3.4253254, "fiftyDayAverageChange": -0.009739876, "fiftyDayAverageChangePercent": -0.0016633325, "longName": "Coya Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1672324200000, "twoHundredDayAverageChange": -0.46117496, "twoHundredDayAverageChangePercent": -0.07312026, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-12-29", "cryptoTradeable": false, "displayName": "Coya Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-01"}]